UBE2N antibody - middle region (ARP33126_T100)
- Known as:
- UBE2N (anti-) - middle region (ARP33126_T100)
- Catalog number:
- arp33126_t100
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- UBE2N antibody - middle region (ARP33126_T100)
Related genes to: UBE2N antibody - middle region (ARP33126_T100)
- Gene:
- UBE2N NIH gene
- Name:
- ubiquitin conjugating enzyme E2 N
- Previous symbol:
- -
- Synonyms:
- UbcH-ben, UBC13, MGC8489
- Chromosome:
- 12q22
- Locus Type:
- gene with protein product
- Date approved:
- 1997-04-16
- Date modifiied:
- 2016-11-09
Related products to: UBE2N antibody - middle region (ARP33126_T100)
Related articles to: UBE2N antibody - middle region (ARP33126_T100)
- Lung cancer is the most common cause of cancer-related deaths. Despite recent advances in therapy, patients invariably develop resistance to standard treatments. Hence, there is an increasing need to identify newer treatment approaches to enhance the efficacy of currently used agents and improve outcomes. - Source: PubMed
Publication date: 2026/02/28
Appadurai Muthamil IniyanAlsafwani Zahraa WajihChaudhary SanjibShah AshuSomavarapu PranayDooshety Sriman NKubicek Ben SBatra Surinder KLakshmanan ImayavarambanGanti Apar Kishor - : Colorectal cancer (CRC) is a major contributor to cancer-related deaths worldwide. While existing screening tools are effective, their high cost and limited availability restrict widespread adoption, particularly in low- and middle-income settings. The identification of affordable, non-invasive biomarkers is therefore critical to improve early CRC detection and survival outcomes. : A systematic literature search was performed through PubMed, ScienceDirect, Medline, ISI Web of Knowledge, and Google Scholar to identify studies reporting stool- and blood-based biomarkers for CRC detection. Data were extracted using a standardized template, including study details, specimen type, detection method, and diagnostic performance parameters such as sensitivity and specificity. : DNA methylation biomarkers demonstrated high diagnostic potential. and achieved a combined stool sensitivity of 91.35%. Other methylation markers, including , , and , showed a composite sensitivity of 82.7%. Plasma-based methylation markers such as , , and reported sensitivities ranging from 18-47% and specificities of 93-99%. Hypermethylation of and achieved 81.3% sensitivity in CRC and precursor lesions. ( and ) were elevated in CRC patients, with stool yielding 72.2% sensitivity and 95% specificity. A stool gene panel (, , , ) reached 96.6% sensitivity and 89.7% specificity, while a methylation-based panel (, , , , , , ) achieved 90.7% sensitivity. MicroRNAs (, , , ) showed excellent diagnostic performance, with sensitivities exceeding 96% and specificities above 75%. : DNA methylation and microRNA biomarkers hold strong promises for non-invasive CRC screening. Multi-marker panels demonstrate superior diagnostic accuracy and may provide a cost-effective, scalable approach for early CRC detection in resource-limited settings. - Source: PubMed
Publication date: 2025/12/27
Hallom PumelelaNaidoo PragalathanSenzani SibusisoKader Sayed SMkhize-Kwitshana Zilungile L - Colon cancer (CC) stands as one of the most prevalent malignant neoplasms worldwide. Despite extensive investigations on the function of T cells in antitumor immunity and dynamics of tumor microenvironment (TME), their precise molecular contributions to the CC progression remain incompletely characterized. Differential gene expression analysis was implemented leveraging TCGA-COAD transcriptomic data, followed by the identification of T cell signature genes using single-cell RNA sequencing (scRNA-seq) dataset. Through intersectional analysis and subsequent prognosis-related gene screening using least absolute shrinkage and selection operator (LASSO) regression and multivariate Cox proportional hazards models, a prognostic model was established. Moreover, its performance was evaluated via receiver operating characteristic (ROC) curves. Participants were split into high-risk and low-risk cohorts based on risk scores, to explore potential immunological differences between groups. A prognostic model was developed based on seven genes, encompassing UBE2N, TUBA1C, FXR1, CBLB, YTHDC1, GPRIN3, and AGPAT2. The area under the ROC curve (AUC) for the training cohort at 3, 5, and 7 years reached 0.676, 0.715, and 0.721, respectively. External validation using three GEO datasets demonstrated consistent predictive performance of the model. The AUC values at 3, 5, and 7 years were 0.632, 0.617, and 0.582 in GSE39582, 0.689, 0.755, and 0.951 in GSE17537, and 0.667, 0.653, and 0.649 in GSE161158. The identified T cell signature genes may function as potential therapeutic targets, while the developed prognostic model and nomogram may facilitate clinical decision-making for CC management. - Source: PubMed
Publication date: 2026/01/02
Wang PeijueLi Yongxiang - Among multiple complications of Kawasaki disease (KD), coronary artery lesions (CALs) emerge as the clinically paramount concern. Aspirin therapy can reduce the incidence of KD with CAL, yet its mechanism remains unclear. This study principally investigated the mechanism by which aspirin is effective in treating KD with CAL. Peripheral blood samples from healthy, KD, and KD + CAL children were analyzed using RT-qPCR, western blot, and ELISA to assess the levels of TNF receptor associated factor 6 (TRAF6), signal transducer and activator of transcription 3 (STAT3), and Th17 cells. Spleen CD4 T cells extracted from mouse were initially activated and subsequently differentiated into Th17 cells for subsequent experiments. After aspirin treatment and the downregulation of TRAF6, IF, ELISA, western blot, and RT-qPCR assessed Th17 differentiation and TRAF6/STAT3 expression. Conversely, the effects of TRAF6 overexpression coupled with MG132 treatment on STAT3 expression were evaluated using RT-qPCR and western blot. Additionally, IP and IF assays were conducted to detect the interaction and ubiquitination modifications between TRAF6 and STAT3. The STRING online tool predicted the interacting proteins of TRAF6, which were then validated through cell experiments. In KD with CAL children, elevated Th17 cell count, reduced TRAF6 expression, and heightened STAT3 expression were observed in the peripheral blood. In cell experiments, aspirin boosted TRAF6 expression, downregulated STAT3, inhibited Th17 differentiation. Dampening TRAF6 expression in cells reversed the impact of aspirin. TRAF6 facilitated the ubiquitination of STAT3, triggering its protein degradation, while UBE2N interacted with TRAF6 to modulate STAT3 expression. This study found that aspirin upregulates TRAF6 to ubiquitinate STAT3, inhibiting Th17 differentiation and improving KD with CAL. - Source: PubMed
Qu XiangzhenMa WeinaMa XiujieLiu JianYang XianghongHe DiSun Yi - The lncRNA/microRNA/mRNA competing endogenous RNA (ceRNA) network has been implicated in the progression of various cancers. However, its role in breast cancer prognosis remains largely unexplored. Exosomes, as mediators of intercellular communication, regulate tumor-associated macrophages (TAMs) polarization by transferring biomolecules. The mechanism by which exosomal MIR4435-2HG diverted from breast cancer cell modulates TAMs polarization, however, has not been fully elucidated. Here, we demonstrate that overexpression of MIR4435-2HG in breast cancer correlates with poor patient prognosis. Functionally, MIR4435-2HG enhances breast cancer cell proliferation, migration, invasion, angiogenesis, and epithelial-mesenchymal transition (EMT) in vitro while driving tumor growth and metastasis in vivo. Mechanistically, MIR4435-2HG as a ceRNA inhibits the degradation of target gene UBE2N by absorbing miR-205-5p. This ceRNA network facilitates breast cancer progression by activating the Wnt/β-catenin signaling pathway. Furthermore, breast cancer cell-derived exosomes deliver MIR4435-2HG to TAMs, promoting M2 polarization through C/EBPβ activation, which further exacerbates cancer progression. Collectively, our findings unveil a novel MIR4435-2HG/miR-205-5p/UBE2N ceRNA network that drives breast cancer progression and highlights exosomal MIR4435-2HG as a critical mediator of TAM polarization, offering potential as a potential biomarker and therapeutic target for breast cancer. - Source: PubMed
Publication date: 2025/11/27
Zhang RuiMeng ZiqiWu XuweiPiao ZhengriJin TiefengZhang Meihua